how this test is relevant Neutrophil to Lymphocyte Ratio and utilied in our normal diagnostic practice?
Neutrophil to Lymphocyte Ratio NLR clinical significance diagnostic utility
Immunotherapy for the Treatment of Hepatocellular Carcinoma
Page 13
NLR inflammatory marker infection sepsis cancer prognosis
Urological Infections
Page 36
NLR = Absolute Neutrophil Count ÷ Absolute Lymphocyte Count
| Category | NLR Value |
|---|---|
| Normal (healthy adults) | 1.0 – 3.0 |
| Mildly elevated | 3.0 – 5.0 |
| Significantly elevated | > 5.0 |
| Critically elevated | > 10.0 |
CBC with Differential ordered
↓
Calculate NLR = ANC ÷ ALC
↓
┌─────────────────────────────────────────────┐
│ NLR < 3 → Likely normal / low risk │
│ NLR 3–5 → Mild inflammation / monitor │
│ NLR 5–10 → Significant — investigate │
│ (infection, malignancy, ACS) │
│ NLR > 10 → Severe systemic stress — │
│ sepsis, advanced cancer, │
│ critical illness │
└─────────────────────────────────────────────┘
| Feature | NLR | CRP | Procalcitonin | ESR |
|---|---|---|---|---|
| Cost | Free (from CBC) | Low | High | Low |
| Turnaround | Immediate | 1–2 hrs | 2–4 hrs | Hours |
| Bacterial vs viral differentiation | Moderate | Poor | Good | Poor |
| Cancer prognosis | Strong | Moderate | Poor | Poor |
| Cardiac risk | Strong | Good | Moderate | Poor |
| Trend monitoring | Yes | Yes | Yes | Yes |
Please share the cut off value for differential diagnosis
Neutrophil to Lymphocyte Ratio NLR cutoff values differential diagnosis bacterial viral infection
NLR threshold cutoff sepsis cancer cardiovascular autoimmune disease specific values
Key principle: NLR cutoffs are condition-specific, not universal. The same value of 5 means very different things in a post-operative patient vs. an outpatient with fatigue. Always apply cutoffs within clinical context.
| NLR Value | Interpretation |
|---|---|
| < 3.0 | Likely viral infection or no significant bacterial infection |
| 3.0 – 5.0 | Borderline — mild bacterial infection possible; monitor |
| > 5.0 | Suggests bacterial infection; warrants further workup |
| > 10.0 | Strong suspicion for severe bacterial infection / early sepsis |
| > 15.0 | Likely sepsis / systemic sepsis — urgent intervention |
| > 25.0 | Septic shock territory; associated with high mortality |
In COVID-19 specifically, NLR > 3.13 on admission predicted severe disease (ICU/ventilation need).
| NLR Cutoff | Clinical Significance |
|---|---|
| > 5.9 | Predictor of sepsis (sensitivity ~80%, specificity ~74% in multiple studies) |
| > 10 | Associated with ICU admission and organ dysfunction |
| > 13 | Linked to 28-day mortality in sepsis patients |
| > 20–25 | Septic shock; mortality risk markedly elevated |
| Condition | NLR Cutoff | Significance |
|---|---|---|
| Acute MI (STEMI/NSTEMI) | > 3.3 – 5.0 | Independent predictor of in-hospital mortality |
| Post-MI prognosis | > 5.0 | Higher risk of MACE (major adverse cardiac events) |
| Heart Failure | > 3.5 | Associated with worse functional class and hospitalization |
| Acute Stroke | > 3.4 | Poor neurological outcome and 90-day mortality |
| Peripheral Artery Disease | > 3.0 | Predicts major limb events and cardiovascular death |
| Cancer Type | NLR Cutoff | Significance |
|---|---|---|
| Colorectal Cancer | > 3.0 – 5.0 | Shorter overall survival (OS) and disease-free survival |
| Gastric Cancer | > 2.4 – 3.5 | Poor prognosis, lymph node involvement |
| Pancreatic Cancer | > 4.0 – 5.0 | Worse OS, unresectable disease |
| Hepatocellular Carcinoma (HCC) | > 3.0 | Poor response to sorafenib and immunotherapy |
| Lung Cancer (NSCLC) | > 3.5 – 5.0 | Shorter OS; predicts poor response to chemotherapy |
| Breast Cancer | > 3.3 | Worse prognosis, triple-negative subtype correlation |
| Bladder Cancer | > 2.5 – 3.0 | Recurrence and progression risk |
| Renal Cell Carcinoma | > 3.0 | Poor response to targeted therapy |
| NLR Cutoff | Significance |
|---|---|
| > 3.5 (pre-op) | Increased risk of post-operative complications |
| > 5.0 (pre-op) | Significant morbidity, prolonged hospital stay |
| > 7.0 (post-op day 1) | Suggests anastomotic leak or surgical site infection |
| Condition | NLR Cutoff | Significance |
|---|---|---|
| Rheumatoid Arthritis | > 3.0 | Active disease; correlates with DAS28 score |
| SLE (Lupus) | > 3.5 | Flare activity, renal involvement risk |
| IBD (Crohn's/UC) | > 2.5 – 3.0 | Active flare vs. remission |
| Appendicitis | > 3.5 | Helpful adjunct to clinical scoring (Alvarado score) |
| Acute Pancreatitis | > 9.5 | Predicts severe pancreatitis (Ranson-equivalent utility) |
| Condition | NLR Cutoff | Significance |
|---|---|---|
| Type 2 Diabetes | > 2.2 | Associated with poor glycemic control and complications |
| NAFLD/NASH | > 1.8 – 2.5 | Correlates with fibrosis stage |
| COVID-19 | > 3.13 | Severe disease predictor on admission |
| COVID-19 | > 6.0 | ICU admission and mechanical ventilation risk |
NLR Range │ Likely Clinical Context
─────────────────┼────────────────────────────────────────────
< 1.0 │ Possible viral illness, autoimmune flare,
│ steroid use (check lymphocytosis)
1.0 – 3.0 │ NORMAL — healthy individual
3.0 – 5.0 │ Mild inflammation / early bacterial infection
│ Metabolic disease, stable malignancy
5.0 – 10.0 │ Moderate — bacterial infection, ACS, cancer
│ progression, surgical stress
10.0 – 15.0 │ Severe infection / sepsis / advanced cancer
> 15.0 – 25.0 │ Septic shock, critical illness, fulminant
│ malignancy
> 25.0 │ Extreme systemic stress — high mortality risk
| Factor | Effect on NLR |
|---|---|
| Corticosteroids | Falsely elevates (↑ neutrophils, ↓ lymphocytes) |
| Post-operative state | Falsely elevates — NLR peaks day 1–3 post-surgery |
| Chemotherapy | Falsely elevates due to lymphopenia |
| Physiological stress (trauma, exercise) | Transient elevation |
| Pregnancy | Baseline NLR slightly higher (2.5–4.5) |
| Elderly (> 65 yrs) | Higher baseline; use > 3.5 as threshold |
| HIV / Immunosuppression | Lymphopenia → falsely high NLR |